UK markets closed
NIKKEI 225
38,385.73 +29.67 (+0.08%) HANG SENG
19,073.71 -41.35 (-0.22%) CRUDE OIL
78.87 +0.85 (+1.09%) GOLD FUTURES
2,392.50 +32.60 (+1.38%) DOW
39,908.00 +349.89 (+0.88%) Bitcoin GBP
51,979.16 +3,439.88 (+7.09%)
Bristol-Myers Squibb Company (BMY.MX)
Mexico - Mexico Delayed price. Currency in MXN
Add to watchlist
At close: 01:55PM CST
| Previous close | 773.49 |
| Open | 755.00 |
| Bid | 739.59 x 1400 |
| Ask | 764.99 x 3800 |
| Day's range | 773.49 - 773.49 |
| 52-week range | 733.03 - 1,208.15 |
| Volume | |
| Avg. volume | 3,747 |
| Market cap | 1.568T |
| Beta (5Y monthly) | 0.44 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 41.17 (5.32%) |
| Ex-dividend date | 04 Apr 2024 |
| 1y target est | N/A |
- Business Wire
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial
PRINCETON, N.J., May 10, 2024--Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial
- Business Wire
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
PRINCETON, N.J., May 07, 2024--Bristol Myers Squibb to Participate in Upcoming Investor Conferences
- Business Wire
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
PRINCETON, N.J., May 06, 2024--U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
© 2024 Yahoo. All rights reserved.